PMID- 36092932
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220913
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 13
DP  - 2022
TI  - A novel prognostic and therapeutic target biomarker based on necroptosis-related 
      gene signature and immune microenvironment infiltration in gastric cancer.
PG  - 953997
LID - 10.3389/fgene.2022.953997 [doi]
LID - 953997
AB  - Background: Gastric cancer is a major global public health burden worldwide. 
      Although treatment strategies are continuously improving, the overall prognosis 
      remains poor. Necroptosis is a newly discovered form of cell death associated 
      with anti-tumor immunity. Methods: Gastric cancer (GC) data from The Cancer 
      Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were downloaded. 
      Bioinformatics analysis was performed to construct a necroptosis-related risk 
      model and to establish cancer subtypes. Potential associations of the tumor 
      immune microenvironment and immunotherapy response with necroptosis-related 
      prognostic risk score (NRG risk score) were comprehensively explored. 16 GC and 
      paired normal tissues were collected and RT-PCR was performed to examine 
      expression of NRG related genes. Results: GC samples were stratified into three 
      subtypes according to prognostic necroptosis gene expression. A necroptosis risk 
      model based on 12 genes (NPC1L1, GAL, RNASE1, PCDH7, NOX4, GJA4, SLC39A4, BASP1, 
      BLVRA, NCF1, PNOC, and CCR5) was constructed and validated. The model was 
      significantly associated with the OS and PFS of GC patients and the tumor immune 
      microenvironment including immune cell infiltration, microsatellite instability 
      (MSI) status, tumor mutational burden (TMB) score, immune checkpoint, and human 
      leukocyte antigen (HLA) gene expression. A prognostic nomogram based on the 
      NRG_score was additionally constructed. A low NRG risk score was correlated with 
      high tumor immunogenicity and might benefit from immunotherapy. Conclusion: We 
      have identified a useful prognostic model based on necroptosis-related genes in 
      GC and comprehensively the relationship between necroptosis and tumor immunity. 
      Predicting value to immunotherapy response is promising, and further research to 
      validate the model in clinical practice is needed.
CI  - Copyright (c) 2022 Xin, Man, Yang and Wang.
FAU - Xin, Dao
AU  - Xin D
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Man, Yuxin
AU  - Man Y
AD  - Department of Medical Oncology, Sichuan Cancer Hospital, Medical School of 
      University of Electronic Science and Technology of China, Chengdu, China.
FAU - Yang, Yalan
AU  - Yang Y
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Wang, Feng
AU  - Wang F
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220825
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC9452725
OTO - NOTNLM
OT  - cancer subtypes
OT  - gastric cancer
OT  - immunotherapy
OT  - necroptosis
OT  - prognostic model
OT  - tumor immune microenvironment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/13 06:00
MHDA- 2022/09/13 06:01
PMCR- 2022/08/25
CRDT- 2022/09/12 04:23
PHST- 2022/06/07 00:00 [received]
PHST- 2022/07/27 00:00 [accepted]
PHST- 2022/09/12 04:23 [entrez]
PHST- 2022/09/13 06:00 [pubmed]
PHST- 2022/09/13 06:01 [medline]
PHST- 2022/08/25 00:00 [pmc-release]
AID - 953997 [pii]
AID - 10.3389/fgene.2022.953997 [doi]
PST - epublish
SO  - Front Genet. 2022 Aug 25;13:953997. doi: 10.3389/fgene.2022.953997. eCollection 
      2022.